Early Recurrence Limits Post-recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy
Authors:
- 9 October 2026
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-9
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitorsInternational Journal of Clinical Oncology, 2025
- Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesInternational Journal of Clinical Oncology, 2025
- Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)Journal of Hepato-Biliary-Pancreatic Sciences, 2022
- Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English editionJournal of Hepato-Biliary-Pancreatic Sciences, 2020
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancerBritish Journal of Surgery, 2018
- Biliary tract cancer registry in Japan from 2008 to 2013Journal of Hepato-Biliary-Pancreatic Sciences, 2015
- Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteriaSurgery Today, 2015
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary AdenocarcinomaJAMA, 2012
- Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in JapanJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in JapanJournal of Hepato-Biliary-Pancreatic Surgery, 2002